Myeloproliferative neoplasms increase risk for arterial and venous thrombosis


Clinical question: What are the risks for arterial and venous thrombosis in patients with myeloproliferative neoplasms (MPNs)?

Background: Myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Prior studies have investigated the incidence of arterial and venous thrombosis in patients with mye­loproliferative neoplasms, but the actual magnitude of thrombosis risk relative to the general population is unknown.

Study design: Retrospective matched-cohort study.

Setting: Sweden, using the Swedish Inpatient and Cancer Registers.

Dr. Arkady Komsoukaniants, Division of Hospital Medicine, UC San Diego Health

Dr. Arkady Komsoukaniants

Synopsis: Using data from 1987 to 2009, 9,429 patients with MPNs were compared with 35,820 control participants to determine hazard ratios for arterial thrombosis, venous thrombosis, and any thrombosis. The highest hazard ratios were seen within 3 months of MPN diagnosis, with hazard ratios of 4.0 (95% confidence interval, 3.6-4.4) for any thrombosis, 3.0 (95% CI, 2.7-3.4) for arterial thrombosis, and 9.7 (95% CI, 7.8-12.0) for venous thrombosis. Risk decreased but remained significantly elevated through follow-up out to 20 years after diagnosis. This decrease was thought to be caused by effective thromboprophylactic and cytoreductive treatment of the MPN.

This study demonstrates significantly elevated risk for thrombosis in patients with MPNs, highest shortly after diagnosis. It suggests the importance of timely diagnosis and treatment of MPNs to decrease early thrombosis risk.

Bottom line: Patients with MPNs have increased rates of arterial and venous thrombosis, with the highest rates within 3 months of diagnosis.

Citation: Hultcrantz M et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. Ann Intern Med. 2018 Mar 6;168(5):317-25.

Dr. Komsoukaniants is a hospitalist at UC San Diego Health and an assistant clinical professor at the University of California, San Diego.

Recommended Reading

The ‘holy grail’ of thrombosis prevention
The Hospitalist
VTE risk after bariatric surgery should be assessed
The Hospitalist
Impaired kidney function no problem for dabigatran reversal
The Hospitalist
Does warfarin cause acute kidney injury?
The Hospitalist
First reversal agent for apixaban and rivaroxaban gets fast-track approval
The Hospitalist
Design limitations may have compromised DVT intervention trial
The Hospitalist
LAAC in nonvalvular AF provides stroke protection comparable to warfarin
The Hospitalist
Skip the catheter-directed thrombolytics
The Hospitalist
DOAC’s edge over warfarin fades with low adherence
The Hospitalist
RBC transfusions with surgery may increase VTE risk
The Hospitalist
   Comments ()